We found a high mutational burden in the overall target (386 mutation/Mb), the genes which are listed in Table S2 with decreasing damaging mutation burden, the most highly mutated genes are KIR2DL1, KIR2DL3, AQP7, HLA-DRB5, SAA2, HLA-A, KIR3DL1, HLA-DPB1, HLA-C, CCL22 are involved in immune response, whereas mutated genes are enriched for metabolic, immunorelated and cancer-related pathways. Here, CCL22 is linked to cancer.